The Aggressive Lymphoma Service is part of Clinical Haematology formed by Peter Mac and the Royal Melbourne Hospital.
Biography
Dr Kylie Mason is a Clinical Haematologist and translational researcher with a joint appointment at The University of Melbourne (NHMRC felowship). She leads the Late Effects and Survivorship stream within the VCCC, and has an interest in Adolescent and Young Adult (AYA) Haematology, with an honorary appointment at OnTrac - Youth Cancer Services.. Dr Mason has a research interest in lymphoma and CLL and is the lead investigator in a number of clinical trials. She also oversees the Sickle cell anaemia / Thalassaemia program at RMH / VCCC. Dr Mason is a member of the national PBAC economics subcommittee and the Clinical Oncology Society of Australasia (COSA) AYA executive committee.
Awards
2015 RMH Research Medal - Winner
2014 RMH Research Medal - Highly commended
2012 L'Oreal Australia For Women In Science Fellowship - Winner
2011 L'Oreal Australia For Women In Science Fellowship - Highly commended
2009 Premier’s Award for Health and Medical Research, Victorian State Government
2007 Student Seminar prize, Walter & Eliza Hall Institute of Medical Research
2008 Young Tall Poppy Science Award
2006 Cleveland Young Investigator’s Award, Royal Melbourne Hospital
2006 Albert Baikie Memorial Medal – Haematology Society Australia & New Zealand
1996 Young Victorian Achiever of the Year, Victorian State Government
1996 Finalist, Young Australian of the Year
1996 Young Australian of the Year Community Service Award Winner
Qualifications
M.B.B.S., PhD, FRACP, FRCPA
Publications
Andrew J. Souers, Joel D. Leverson, Edwin R Boghaert, Scott L. Ackler, Nathanial D Catron, Jun Chen, Brian D. Dayton, Hong Ding, Sari L. Enschede, Wayne J. Fairbrother, David C.S. Huang, Sarah G. Hymowitz, Sha Jin, Seong Lin Khaw, Peter J. Kovar, Lloyd T Lam, Jackie Lee, Kennan C. Marsh, Heather L. Maecker, Kylie D. Mason, Michael J. Mitten, Paul M. Nimmer, Andrew Oleksijew, Chang H. Park, Cheol-Min Park, Darren C. Phillips, Andrew W Roberts, Deepak Sampath, John F. Seymour, Morey L. Smith, Gerard M. Sullivan, Stephen K. Tahir, Chris Tse, Michael D. Wendt, Yu Xiao, John C. Xue, Haichao Zhang, Rod A. Humerickhouse, Saul H. Rosenberg, Steven W. Elmore. Potent anti-tumor activity through selective inhibition of Bcl-2: ABT-199 induces apoptosis in Bcl-2-dependent malignancies while sparing platelets. Nature Medicine 2013; 9: 202–208
Mason KD, Carpinelli M, Fletcher J, Collinge J, Hilton A, Ellis S, Kelly P, Ekert P, Metcalf D, Roberts AW, Huang DCS, Kile BT ; Programmed anuclear cell death delimits platelet life span. Cell, 2007; 128, 1173-1186. (Impact factor 29.4) Cited as ‘Exceptional’ by Faculties of 1000 in Medicine and Biology.
Kylie D. Mason, Cassandra J. Vandenberg, Clare L. Scott, Andrew H. Wei, Suzanne Cory, David C.S. Huang, Andrew Roberts; In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Science 2008; 105(46): 17961-6.
Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie D, Grigg AP, Seymour JF, Szer J, Huang DCS, Roberts AW; The BH3 mimetic compound ABT-737 Synergizes with a Range of Cytotoxic Chemotherapy Agents in Chronic Lymphocytic Leukemia. Leukemia, 2009; 23(11): 2034-41 (Impact factor: 8.6)
Related links
Haematology
Aggressive Lymphoma
Non-Malignant Haematology
Long Term Follow Up and Survivorship
